EUVIMEDEUVIMED entdecken
Crossref

Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody–Drug Conjugates

Xiaoli Liao iD, Anthony Haight, Dennie Welch, Linjie Han

Bioconjugate Chemistry · 2023

DOI: 10.1021/acs.bioconjchem.3c00425 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2023. Verfasst von Xiaoli Liao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Process Chemistry, Small Molecule CMC Development, AbbVie Inc., North Chicago, Illinois 60064, United States. Hauptthemen laut MEDLINE: Immunoconjugates. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Developing site-specific conjugation technologies for antibody-drug conjugates (ADCs) aims to produce more homogeneous and controlled drug-loaded ADCs to reduce variability and thereby improve the therapeutic index. This article presents a technology that uses cysteine mutant antibodies and mild phosphine-based reductants to prepare site-specific ADCs. The two types of cysteine mutant antibodies, designated C6v1 and C6v2, have one of the interchain disulfide-forming cysteines in the Fab region in the light chain (LC214) or in the heavy chain (HC220) substituted by alanine (or other amino acids), respectively. Certain phosphine-based reductants were found to selectively reduce the "unpaired" cysteines, at the heavy chain (HC220) for C6v1 or at the light chain (LC214) for C6v2 while keeping the interchain disulfide bonds in the hinge region intact, resulting in 90% of DAR2 species and more than 95% of the desired specific conjugation at HC or LC following conjugation to maleimide moieties. The reduction method shows consistent selectivity toward various C6v1 or C6v2 antibody backbones. Sensitivity toward buffer pH for some reductants can be used to optimize reductant reactivity and selectivity. The technology can be further expanded to generate site-specific DAR4 or dual-payload ADCs based on C6v1 or C6v2 antibodies. This technology offers a method to control drug-loading and conjugation sites using a mild one-pot process, as compared to the reduction-oxidation methods used in technologies such as THIOMAB, and shows superior DAR profiles and process simplification as compared to other selective reduction methods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesCysteineReducing AgentsAntibodiesDisulfidesPhosphines

Substanzen

ImmunoconjugatesCysteineReducing AgentsAntibodiesDisulfidesphosphinePhosphines

Autor:innen und Institutionen

  • Process Chemistry, Small Molecule CMC Development, AbbVie Inc., North Chicago, Illinois 60064, United States.
  • Analytical Development, Operations S&T, AbbVie Bioresearch Center, Worcester, Massachusetts 01605, United States.

ORCID-Profile: Xiaoli Liao

Förderung

  • AbbVie

Zitieren

APA

Liao, X., Haight, A., Welch, D., & Han, L. (2023). Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody–Drug Conjugates. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.3c00425

Vancouver

Liao X, Haight A, Welch D, Han L. Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody–Drug Conjugates. Bioconjugate Chemistry. 2023. doi:10.1021/acs.bioconjchem.3c00425

BibTeX
@article{Liao2023,
  author = {Liao, Xiaoli and Haight, Anthony and Welch, Dennie and Han, Linjie},
  title = {Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody–Drug Conjugates},
  journal = {Bioconjugate Chemistry},
  year = {2023},
  doi = {10.1021/acs.bioconjchem.3c00425}
}
Kostenlos starten →